

## **Workshop: Genomics in Cancer Risk Assessment**

August 27-28, 2009 San Servolo, Venice, Italy



## Parallel Satellite Workshop:

10th International Conference on Environmental Mutagens (ICEM) Aug 20-25 2009 Firenze VII World Congress on Alternatives & Animal Use in the Life Sciences Aug 30 –Sept 3, 2009 Rome

## Organizing committee:

Jiri Aubrecht, Pfizer/HESI Genomics Committee
Raffaella Corvi, European Centre for the Validation of Alternative Methods (EC ECVAM), JRC
Bernward Garthoff, Bayer CropScience
Jos Kleinjans, Maastricht University/carcinoGENOMICS
Anneloes Melman, Maastricht University/carcinoGENOMICS
Raegan O'Lone, Health and Environmental Sciences Institute (HESI)
Richard S. Paules, NIEHS/HESI Genomics Committee
Rene Reijnders, Maastricht University/carcinoGENOMICS

## **Program**

Thursday, August 27, 2009

9:00 am	Welcome and Introduction
	Richard S. Paules, NIEHS, NIH, US
9:15 - 9:45 am	Keynote Address I
THE PARTY	Elizabeth Mansfield, US FDA
	Genomics at the US Food and Drug Administration (FDA)
9:45 - 10:00 am	Break
10:00 - 12:10 am	Session I. Current Approaches in Cancer Risk Assessment for Drugs and Chemicals; Session Chair - Bernward Garthoff
7-4	<b>Jan-Willem van der Laan,</b> EMEA/RIV <mark>M</mark> , National Institute of Public Health & Environment, The Netherlands
	Carcinogenic Risk Assessment of Human Pharmaceuticals: A European Regulatory Perspective
	Wim de Coen, European Chemicals Agency, Helsinki
	REACH Regulation: Overview and Application of Integrated Testing Strategies
	Kate Guyton, US Environmental Protection Agency
	Consideration of Multiple Mechanisms of Carcinogenesis in Human

12:10 - 1:10 pm **Lunch** 

1:10 - 3:20 pm **Session II. In Vivo Approaches in Carcinogen Risk Assessment**; Session Chair - Richard Paules

Laura Suter, Hoffmann-LaRoche, Basel

Use of Gene Expression Profiling for the Prediction of Toxicity

Health Risk Assessment of Environmental Contaminants















Hans-Juergen Ahr, Bayer Healthcare AG

Carcinogen Specific Expression Profiling In Vivo: Prediction of Carcinogenic Potential?

Richard Irwin, NTP/NIEHS, NIH, US

Prediction of Hepatocarcinogenic Potential of Chemicals Using Hepatic Transcript Profiles from Prechronic Exposure Data

Mark Fielden, Amgen, US

Integrating Predictive and Mechanistic Carcinogenomic Biomarkers into Drug Discovery and Development

3:20 - 3:35 pm

**Break** 

3:35 - 5:45 pm

Session III. In Vitro Approaches in Carcinogen Risk Assessment; Session Chair - Jiri Aubrecht

Joost H. M. van Delft, Maastricht University

In Vitro Liver Models for Genomics Based Cancer Risk Assessment

**Jiri Aubrecht,** Pfizer, US

Scientific and Regulatory Challenges in the Development and Application of Toxicogenomic Biomarkers Derived from In Vitro Cell Systems

Robert J. Kavlock, US EPA (ToxCast)

Developing Predictive Bioactivity Signatures of Carcinogenesis with ToxCast HTS Data

Raffaella Corvi, EC ECVAM, JRC, Ispra

Validation of Alternative Meth<mark>od</mark>s for Genotoxicity and Carcinogeni<mark>ci</mark>ty Safety Assessm<mark>en</mark>t

6:30 - 7:30 pm

**Poster Session** 

7:30 pm

**Welcome Reception** 

Friday, August 28, 2009

8:30 - 10:40 am

Session IV. Human Carcinogen Risk Assessment; Session Chair - Richard Paules

**Leona Samson,** Massachusetts Institute of Technology, US

Complex Biological Responses to Carcinogenic Agents

Martyn Smith, University of California, Berkeley, US

Toxicogenomic Profiling of Exposed Humans to Identify Hazards, MOA, Low-Dose Adverse Effects and Disease Risk

Kenneth Ramos, University of Louisville (USA)

TBD

**Soterios Kyrtopoulos**, National Hellenic Research Foundation, Athens (the new EU FP7project EnviroGenoMarkers)

Exploring the Potential of Omics in Population Studies: The EnviroGenomarkers Project

10:40 - 10:55	Break
10:55 - 12:35 pm	Session V. 'Omics' and Risk Assessment in the 21st Century; Session Chair - Jos Kleinjans
	<b>Vera Rogiers,</b> Free University, Brussels
	Functional and Stable Culture Models are Key Factors in the Risk Assessment Process of Carcinogens
	Jonathan Moggs, Novartis, Basel
	Epigenomics - Novel Insights into Mechanisms and Biomarkers for Non-Genotoxic Carcinogenesis
	Christopher J. Portier, NIEHS, NIH, US
1	Findings Pathways Associated with Toxicity
12:35 - 1:45 pm	Lunch
1:45 - 3:25 pm	Session VI. Challenges for the Future in Carcinogen Risk Assessment; Session Chair - Raffaella Corvi
	John Doe, ECETOC & Syngenta
	The Future Risk Assessment for Carcinogenicity for Chemicals and Pesticides
19.00	Paul Carmichael, Unilever, UK
LILA	The Contribution of 'Omics' into the Cancer Risk Assessment of Cosmetic Ingredients - The In Vitro Challenge
المنا العدا	James MacDonald, Chrysalis Pharma Consulting, US  A View of Future Opportunities
3:25 - 3:40 pm	Break
3:40 - 4:25 pm	Keynote Address II
	Hans Lehrach, Max Planck Institute for Molecular Genetics, Berlin Omics in the Present and Future of Human Medicine
4:25 - 5:45 pm	Session VII. Panel Discussion - The Way Forward and the Role of Genomics; Session Chairs - Jiri Aubrecht and Jos Kleinjans
	David Rouquie, BayerCropScience, Sophia Antipolis
	James S. Bus, Dow Chemical
	Nina Hallmark, ExxonMobil
	<b>Beatriz Silva Lima</b> , Natl. Auth. of Med. & Health Products, and University of Lisbon, Portugal
	David Carlander, European Food Safety Authority

Workshop Concluding Remarks - Jos Kleinjans and Jiri Aubrecht

6:30 pm Gala Dinner